Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00456833 · ClinicalTrials.gov registry record · Phase 1

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
248
Enrollment target
14
Study locations

NCT00456833 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 248 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 14 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00456833, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
248 participants
Enrollment target
14
Study locations

Study Summary

This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG RAD001
  • DRUG erlotinib

Study Locations (14)

Other

  • Novartis Investigative Site - Herlev
  • Novartis Investigative Site - Saint-Herblain Cédex
  • Novartis Investigative Site - Villejuif
  • Novartis Investigative Site - Moscow

Georgia

  • Novartis Investigative Site - Atlanta

Illinois

  • Novartis Investigative Site - Chicago

Massachusetts

  • Novartis Investigative Site - Boston

Minnesota

  • Novartis Investigative Site - Rochester

Tennessee

  • Novartis Investigative Site - Nashville

Texas

  • Novartis Investigative Site - Houston

Wisconsin

  • Novartis Investigative Site - Madison

Trial Details

FieldValue
Enrollment Target 248 participants
Start Date 2005-06
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00456833

The ClinicalTrials.gov registry entry for NCT00456833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which RAD001 is the first listed.

NCT00456833 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Other, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT00456833 about?

NCT00456833 is a clinical study titled "Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy". This study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced Non Small Cell Lung Cancer treated only with chemotherapy as systemic therapy.

What is the current status of trial NCT00456833?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 248 participants. The study started on 2005-06.

What conditions does trial NCT00456833 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT00456833?

The interventions under investigation include: RAD001 (DRUG), erlotinib (DRUG).

Who is sponsoring clinical trial NCT00456833?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00456833 being conducted?

This trial has 14 study locations across Georgia, Illinois, Massachusetts, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.